YDES NASDAQ
YD Bio Limited Ordinary Shares
1W: +2.6%
1M: -0.8%
3M: -57.3%
YTD: -80.6%
$2.30
+0.01 (+0.44%)
Weekly Expected Move ±20.5%
$1
$2
$2
$3
$3
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$162.9M
52W Range1.7-25
Volume42,584
Avg Volume128,517
Beta-0.13
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOEthan Shen
Employees15
SectorHealthcare
IndustryBiotechnology
IPO Date2025-08-29
Websiteydesgroup.com
No. 3, Xingnan St.
Taipei, TP 115001
TW
Taipei, TP 115001
TW
+82 2 546 1611
About YD Bio Limited Ordinary Shares
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
Latest News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
YD Bio Limited GAAP EPS of -$0.12, revenue of $0.6M
YD Bio Limited Reports Full Year 2025 Financial Results
YD Bio Limited Reports Full Year 2025 Financial Results
Autoliv Posts Upbeat Q1 Results, Joins United Airlines, Royal Caribbean Cruises And Other Big Stocks Moving Higher On Friday
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lu Shao-Ta | A-Award | 5,749 | — | 2026-06-30 |
| Lu Shao-Ta | M-Exempt | 5,749 | — | 2026-06-30 |
| Chang Kochi | A-Award | 5,749 | — | 2026-06-30 |
| Chang Kochi | M-Exempt | 5,749 | — | 2026-06-30 |
| Lu Shao-Ta | A-Award | 2,081 | — | 2026-03-31 |